The marketing authorization application seeks approval for oral alitretinoin in the treatment of severe refractory chronic hand eczema (CHE) and is based on a clinical program comprising almost 2000 patients.
Recently, marketing authorization applications for alitretinoin in severe refractory CHE have been submitted to various EU member states.